Shares of Vanda Pharmaceuticals (VNDA-$11.80) rallied 15 percent in the last two days after rumors resurfaced that partner Novartis AG might be interested in a takeover. The drug maker has a total market capitalization of $328 million – less than the value of the companies' drug pact, worth an estimated $465 million. Whether a merger makes financial sense, however, will ultimately depend on the sales performance on Vanda's drug of mutual interest -- the schizophrenia treatment Fanapt.
Is Fanapt more than just another “me-too” second-generation antipsychotic? Continue Reading > ….
Editor David J Phillips does not hold a financial interest in any stocks mentioned in this article. The 10Q Detective has a Full Disclosure Policy.